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Take-home message: The ratio between the
Cv-aCO2 and the arterial-to-venous oxygen
content difference (Da-vO2), as a surrogate
of the VCO2/VO2 ratio (i.e., the respiratory
quotient), may identify patients at risk of
anaerobic metabolism.
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Abstract Purpose: To evaluate
the prognostic value of the Cv-aCO2/
Da-vO2 ratio combined with lactate
levels during the early phases of re-
suscitation in septic shock.
Methods: Prospective observational
study in a 60-bed mixed ICU. One
hundred and thirty-five patients with
septic shock were included. The re-
suscitation protocol targeted mean
arterial pressure, pulse pressure varia-
tions or central venous pressure, mixed
venous oxygen saturation, and lactate
levels. Patients were classified into
four groups according to lactate levels
and Cv-aCO2/Da-vO2 ratio at 6 h of
resuscitation (T6): group 1, lactate
C2.0 mmol/L and Cv-aCO2/Da-vO2
[1.0; group 2, lactate C2.0 mmol/L
and Cv-aCO2/Da-vO2 B1.0; group 3,
lactate\2.0 mmol/L and Cv-aCO2/
Da-vO2[1.0; and group 4, lactate
\2.0 mmol/L and Cv-aCO2/Da-vO2
B1.0. Results: Combination of hy-
perlactatemia and high Cv-aCO2/Da-
vO2 ratio was associated with the worst
SOFA scores and lower survival rates
at day 28 [log rank (Mantel–
Cox) = 31.39, p\ 0.0001]. Normal-
ization of both variables was
associated with the best outcomes.
Patients with a high Cv-aCO2/Da-vO2
ratio and lactate\2.0 mmol/L had
similar outcomes to hyperlactatemic
patients with low Cv-aCO2/Da-vO2
ratio. The multivariate analysis re-
vealed that Cv-aCO2/Da-vO2 ratio at
both T0 (RR 3.85; 95 % CI 1.60–9.27)
and T6 (RR 3.97; 95 % CI 1.54–10.24)
was an independent predictor for
mortality at day 28, as well as lactate
levels at T6 (RR 1.58; 95 % CI
1.13–2.22). Conclusion: Comple-
menting lactate assessment with Cv-
aCO2/Da-vO2 ratio during early stages
of resuscitation of septic shock can better
identify patients at high risk of adverse
outcomes. The Cv-aCO2/Da-vO2 ratio
may become a potential resuscitation
goal in patients with septic shock.
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Introduction
Early identification of tissue hypoperfusion and adequate
resuscitation are key factors in the management of patients
with shock [1, 2]. Although early resuscitation seems to
improve outcomes in severe sepsis and septic shock, the
relative value of resuscitation goals continues to be highly
debated [3–6]. Monitoring of ScvO2 is widely recom-
mended [3–7] although strongly challenged by others [8, 9].
In an early trial, Rivers et al. [3] observed a significant
decrease in mortality when they used a resuscitation bundle
targeting ScvO2[70 %. Conversely, recent data failed to
confirm any benefit with this approach [10]. However, it
should be noted that ScvO2 was normal or near normal at
inclusion in a number of patients in these trials [10] as it has
frequently been reported on admissions to the intensive care
unit in studies subsequent to the River’s trial [11]. More-
over, normalization of systemic hemodynamic and oxygen
metabolism variables does not ensure an adequate tissue
perfusion and does not prevent progression to multiorgan
dysfunction and death [12]. Lactate has also been proposed
as a target for resuscitation therapy. In fact, not only
baseline lactate level [13] but also its evolution under the
influence of therapy [14] has been associated with clinical
outcomes. Despite promising results observed in one trial
[15], no consistent advantages have been found for lactate-
based resuscitation bundles over resuscitation guided by
oxygen parameters [15–17]. Accordingly, additional
markers of inadequate perfusion should be explored,
especially when ScvO2 values are close to normal.
Recently, the venous-to-arterial carbon dioxide differ-
ence (Pv-aCO2) has been proposed as an alternative marker
of tissue hypoperfusion [18, 19]. In fact, persistently high
Pv-aCO2 predicts adverse clinical outcomes independently
of oxygen-derived parameters and it could anticipate lac-
tate variations [20]. However, the Pv-aCO2 may be normal
despite the presence of significant hypoperfusion in high
cardiac output states such as septic shock, where high flows
might prevent venous CO2 accumulation; or inversely, Pv-
aCO2 can increase in the absence of hypoperfusion, in part
due to the Haldane effect [21]. Consequently, CO2 varia-
tions must be evaluated according to O2 changes. Indeed,
CO2 production should not exceed O2 availability during
aerobic metabolism. Thus, the ratio between the Pv-aCO2
and the arterial-to-venous oxygen content difference (Da-
vO2), as a surrogate of the VCO2/VO2 ratio (i.e., the respi-
ratory quotient), may identify patients at risk of anaerobic
metabolism. Using this rationale, Mekontso-Dessap et al.
[22] demonstrated that a Pv-aCO2 to Da-vO2 ratio[1.4 was
superior to Pv-aCO2, SvO2, and Da-vO2 in predicting hy-
perlactatemia in a cohort of critically ill patients.
Importantly, Pv-aCO2/Da-vO2 ratio variations are faster
than lactate kinetics, which make it an attractive variable to
monitor. However, CO2 partial pressure (PCO2) is not
equivalent to CO2 content (CCO2), particularly when O2
saturation varies (Haldane effect). Thus, Cv-aCO2/Da-vO2
variations should better reflect variations in VO2 than Pv-
aCO2/Da-vO2, especially when ScvO2 or SvO2 is low.
As the Cv-aCO2 to Da-vO2 ratio could reflect ongoing
anaerobic metabolism, we hypothesized that an increased
Cv-aCO2/Da-vO2 could be used to identify patients at risk
of adverse outcomes during early stages of septic shock
and that this variable could provide additional informa-
tion when combined with lactate levels.
Materials and methods
We conducted a prospective observational study in a
60-bed mixed ICU in a university-affiliated hospital. The
Fundacio´n Valle del Lili’s ethical and biomedical research
committee approved the current study (protocol number
710; approval number 093-2014). A written informed
consent was waived because all measurements and pro-
cedures routinely followed the local protocols for the
management of severe sepsis and septic shock and no new
therapeutic interventions were performed. Our ‘‘rapid-re-
sponse team’’ evaluated all patients with suspected septic
shock at the emergency room and clinical wards. Resus-
citation was immediately started and these patients were
rapidly admitted to the ICU. Presence of infection was
established using the Centers for Diseases Control and
Prevention criteria [23] and septic shock was defined ac-
cording to the criteria of the American College of Chest
Physicians/Society of Critical Care Medicine Consensus
Conference [24]. Antibiotics were started within 1 h of
diagnosis of sepsis. An arterial catheter was placed in the
radial or femoral artery while a pulmonary artery catheter
(PAC) was inserted via the jugular or subclavian vein
when deemed appropriate according to clinical judgment
and local indications for the use of hemodynamic
monitoring. All patients with a new episode of septic
shock and equipped with a PAC were included for the
study. Patients with a previous episode of severe sepsis or
septic shock within the last 3 months, younger than
18 years old, pregnant women, with limitations of care,
with liver cirrhosis Child–Pugh C, or severe chronic ob-
structive pulmonary disease were excluded.
General management
All patients followed an early quantitative resuscitation
protocol adapted from the Surviving Sepsis Campaign [7]
in order to target (a) mean arterial pressure (MAP)
C65 mmHg; (b) urine output C0.5 mL/kg/min; (c) SvO2
C65 %; (d) normalization of lactate levels. In the case of
attaining the SvO2 goal but with persistently high lactate
levels, additional efforts were performed to attain
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normalization of the latter. Pulse pressure variations were
used to indicate fluid responsiveness whenever applicable.
In other cases, filling pressures and clinical judgment
were used. Fluid resuscitation was conducted by repeated
fluid challenges with crystalloids and/or albumin 4 %.
Hydroxyethyl starches (HES) were not used.
Norepinephrine was the first-choice vasopressor to
maintain MAP goals. Vasopressin titrated to a maximum
of 0.03 UI/min was allowed in order to raise MAP or to
decrease norepinephrine dose but never as a single va-
sopressor. Titrated dobutamine up to 20 lg/kg/min was
used when myocardial dysfunction was demonstrated or
when SvO2 goals were not achieved despite adequate
intravascular volume and MAP. Mechanical ventilation
was provided (when needed) under light sedation (mida-
zolam) and analgesia (fentanyl, morphine); tidal volume
was limited to 6–8 mL/kg. Low dose hydrocortisone was
indicated if vasopressor requirement did not decrease
during the first 6 h of resuscitation despite ensuring ade-
quate intravascular volume. Glycemic control was
adjusted to maintain glucose levels\150 mg/dL. Finally,
stress ulcer and venous thrombosis prophylaxis were
provided according to international recommendations [7].
Study protocol
Time 0 (T0) was stated at the PAC insertion. We recorded
the total volume of fluids received and the time elapsed
between the first episode of hypotension and T0. We
performed complete hemodynamic measurements and
drew blood samples for arterial and mixed-venous gases
analysis (ABL 300, Radiometer Copenhagen, Denmark)
and arterial lactate at T0, and 6 h (T6), around 12 h (T12),
and 24 h (T24) after. Vasopressors and inotropic doses,
respiratory parameters, and total fluids were also regis-
tered at each measurement time. Organ dysfunction at
day 3 was evaluated using the Sequential Organ Failure
Assessment (SOFA) score [25]. We also calculated the
ventilator-free days and survival at day 28.
Carbon dioxide and oxygen variables
We calculated CO2 and O2 variables at T0, T6, T12, and
T24, as follows:
• DO2 = CaO2 9 CI
• VO2 = (CaO2 - CvO2) 9 CI
• ERO2 = (CaO2 - CvO2)/CaO2
• CaO2 = (Hg 9 SaO2 9 1.34) ? (PaO2 9 0.003)
• CvO2 = (Hg 9 SvO2 9 1.34) ? (PvO2 9 0.003)
• Pv-aCO2 = PvCO2 - PaCO2
• Da-vO2 = CaO2 - CvO2
where CaO2 and CvO2 are the arterial and venous O2
content, PaO2 and PvO2 represent their arterial and
venous partial pressures respectively, CI represents the
cardiac index, and ERO2 represents the oxygen extraction
ratio.
We also calculated CO2 contents according to the
Douglas formula [26]:
Blood CO2 content Blood CCO2ð Þ ¼ Plasma CCO2
 1  0:0289  Hb½ ½   3:352  0:456  SpO2½ ½½
 8:142  pH½ 
where plasma CCO2 = 2.226 9 S 9 plasma PCO2 9
(1 ? 10pH - pK
0
); In turn, S (plasma CO2 solubility) and
apparent pK (pK0) are temperature (T, expressed as C)
dependent and calculated according to previous calcula-
tions [27]:
S ¼ 0:0307 þ ½0:00057  ð37  TÞ þ ½0:00002
 ð37  TÞ2
pK 0 ¼ 6:086 þ ½0:042  ð7:4  pHÞ þ ð38  TÞ½ ½
 0:00472 þ 0:00139x 7:4  pH½ f g:
Definitions of the four groups
Considering that in aerobic conditions VCO2 should not ex-
ceed VO2, we considered a Cv-aCO2/Da-vO2 ratio[1.0 as
abnormal. Hence, we analyzed hemodynamic and oxygen
metabolism parameters for four predetermined groups ac-
cording to lactate levels and Cv-aCO2/Da-vO2 attained after
the first 6 h of resuscitation: group 1, lactate C2.0 mmol/L
and Cv-aCO2/Da-vO2 ratio[1.0; group 2, lactate C2.0 m-
mol/L and Cv-aCO2/Da-vO2 ratio B1.0; group 3, lactate
\2.0 mmol/L and Cv-aCO2/Da-vO2 ratio[1.0; and group 4,
lactate\2.0 mmol/L and Cv-aCO2/Da-vO2 ratio B1.0.
Statistics
After demonstrating a non-normal distribution of data
with a Kolmogorov–Smirnoff test, we used a Kruskal–
Wallis test to compare continuous variables with a
Tukey–Kramer test for multiple comparisons among the
predefined groups. v2 test was used to compare discrete
variables (or Fisher’s exact test, when appropriate).
Multiorgan dysfunction at day 3 was evaluated using the
Sequential Organ Failure Assessment (SOFA) score [25]
for the predefined groups. Survival curves up to day 28
were estimated using the Kaplan–Meier method and log-
rank (Mantel–Cox) test was used to estimate differences
among the predefined groups.
In a further analysis, variables were introduced into a
multivariate model if significantly associated with mor-
tality at day 28 at the univariate analysis when a p value
was \0.2. General demographics, hemodynamics, vaso-
pressor use, fluids, and blood gases parameters at T0 and
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T6 were used in the model, previously testing for colli-
nearity. These analyses were also conducted in those
patients attaining SvO2 C65 %. A Hosmer and Lemeshow
test was used to assess the goodness of fit of the model.
Receiver operating characteristic (ROC) curves for the
original model (i.e., the ‘‘large model’’) and a second one
excluding the Cv-aCO2/Da-vO2 ratio (i.e., the ‘‘short
model’’) were constructed in order to test the added value
of the Cv-aCO2/Da-vO2 ratio in predicting mortality at
day 28. The ROC curves were compared using the
method described by DeLong and colleagues [28].
Additional logistic regression models including Pv-
aCO2/Da-vO2 instead of Cv-aCO2/Da-vO2 and another
one including simultaneously Pv-aCO2/Da-vO2 and Cv-
aCO2/Da-vO2 were also conducted to explore its rela-
tionship with mortality at day 28.
Finally, we described the time-course for oxygen
metabolism variables, Pv-aCO2/Da-vO2 and Cv-aCO2/
Da-vO2 during the first 24 h for both survivors and non-
survivors at day 28.
Data are presented as median (25–75th percentiles).
Risk assessments are presented as risk ratios with 95 %
confidence intervals. A p value B0.05 (two-tailed) was
considered significant.
Results
Selection of patients is shown in the Fig. 1 of the Electronic
Supplementary Material (ESM). A total of 135 patients
were included in the study during a period of 18 months.
Mortality at day 28 in this cohort was 42 % and ICU length
of stay was 6 (2–10) days. The time from first hypotension
episode to catheter insertion and blood sampling (i.e., T0)
was 3.0 (2.5–4.0) h and the median amount of fluids re-
ceived before T0 was 1,977 (1,200–2,800) mL.
After the first 6 h of resuscitation, 110 (81 %) patients
achieved a MAP [65 mmHg and 98 (73 %) a SvO2
[65 %. However, 84 (62 %) patients still had an arterial
lactate C2.0 mmol/L and 65 (48 %) had a Cv-aCO2/Da-
vO2 ratio[1.0. Accordingly, 42 patients were classified
into group 1, 42 into group 2, 23 into group 3, and 28 into
group 4. Patients in groups 1 and 2 had higher APACHE
II scores and required higher vasopressor doses at T0
(Table 1). No significant differences were found in de-
mographic data or other hemodynamic variables at T0
(Table 1 and ESM Table 1). All hemodynamic, blood
gases, oxygen parameters, and ventilator settings at both
T0 and T6 are presented in the ESM Table 1. Patients
from groups 1 and 2 had more acidosis at T0 and T6.
Regarding the clinical outcomes, patients from group 1
evolved with higher SOFA scores (Kruskal–Wallis,
p\ 0.001; post hoc test demonstrated significant differ-
ences among groups 1 vs. 3 and 1 vs. 4) (Fig. 1) and they
also had the lowest survival rates at day 28 [log rank
(Mantel–Cox) = 31.39, p\ 0.0001] (Fig. 2). Intriguing-
ly, patients in groups 2 and 3 had similar SOFA scores
and outcomes at day 28 (Table 2). Furthermore, patients
from group 1 had the lowest VO2 at T6 and T12 compared
to all other groups, even though cardiac output, SvO2, and
DO2 were not different (ESM Fig. 2).
Multivariate logistic regression analysis at T0
demonstrated that Cv-aCO2/Da-vO2 was an independent
predictor of mortality at day 28 (RR 3.85; 95 % CI
1.60–9.27). When analysis was performed using the same
variables at T6, Cv-aCO2/Da-vO2 was again related to
higher mortality at day 28 (RR 3.97; 95 % CI
1.54–10.24), in addition to lactate levels (RR 1.58; 95 %
CI 1.13–2.22) (Table 3). An additional multivariate ana-
lysis performed in patients attaining SvO2[65 % showed
that lactate levels (RR 2.41; 95 % CI 1.22–4.76) and Cv-
aCO2/Da-vO2 (RR 5.71; 95 % CI 1.20–27.19) remained
predictors of mortality at day 28 (Table 3). The area un-
der ROC curves for models including or excluding the
Cv-aCO2/Da-vO2 ratio (i.e., the ‘‘large’’ and ‘‘short’’
model, respectively) were significantly different
(AUClarge 0.8542, 95 % CI 0.7797–0.9286 vs. AUCshort
0.7943, 95 % CI 0.7050–0.8836. LR test, v2 17.81,
p\ 0.001; C statistic, v2 4.52, p = 0.03) (Fig. 3).
We also found significant differences in the time-
course of Pv-aCO2, Pv-aCO2/Da-vO2, lactate levels, and
Cv-aCO2/Da-vO2 during the first 24 h of resuscitation
between survivors and non-survivors at day 28 (repeated
measurements ANOVA, p\ 0.05) (ESM Figs. 3–5).
Discussion
We observed that persistent hyperlactatemia combined
with a high Cv-aCO2/Da-vO2 was associated with the
most severe organ dysfunction and worst clinical out-
comes, while simultaneous normalization of lactate and
Cv-aCO2/Da-vO2 ratio was associated with the best out-
comes. Interestingly, patients attaining lactate levels
\2.0 mmol/L combined with Cv-aCO2/Da-vO2[1.0 had
similar outcomes to patients with persistent hyperlac-
tatemia and low Cv-aCO2/Da-vO2 ratio.
We hypothesized that a Cv-aCO2/Da-vO2[1.0 reflects
anaerobic metabolism as VCO2 should not be higher than
VO2 during aerobic conditions. Indeed, occurrence of a
high VCO2/VO2 has been previously reported in ex-
perimental conditions, where lower reductions in VCO2
than in VO2 have been associated with other markers of
tissue hypoxia, suggesting the involvement of a non-aero-
bic source of CO2 [29, 30]. Consequently, a Cv-aCO2/Da-
vO2 ratio[1.0 (as a surrogate of theVCO2/VO2 ratio) could
identify an excess of CO2 generation probably due to
anaerobic metabolism and this condition could be associ-
ated with more unfavorable clinical outcomes as we report


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































et al. [22] tested the hypothesis that Pv-aCO2/Da-vO2 better
detects anaerobic metabolism than other parameters
derived from PAC measurements in critically ill patients.
They found a significant agreement between Pv-aCO2/Da-
vO2 and lactate levels. However, the agreement between
Pv-aCO2/Da-vO2 and lactate levels should not necessarily
be considered as representative of anaerobic metabolism
since hyperlactatemia is not always of hypoxic origin [31,
32]. Interestingly, our data demonstrated that a high Cv-
aCO2/Da-vO2 might be present with normal or high lactate
levels suggesting that these variables evolve independently
probably because lactate kinetics can be slower than Cv-
aCO2/Da-vO2 variations. Thus, in the presence of hyper-
lactatemia a high Cv-aCO2/Da-vO2 may favor anaerobic
metabolism as the possible source of lactate, while a normal
Cv-aCO2/Da-vO2 may suggest that lactate accumulation is
due to other causes [33–36].
Searching for other markers of ongoing tissue hypoxia
could increase the information given by lactate levels
during resuscitation of septic shock. Recently, Rimachi
et al. [37] reported the presence of hyperlactatemia in
65 % of patients with septic shock, but only 75 % of these
patients exhibited increased lactate/pyruvate ratio, con-
firming that hyperlactatemia may be not due to hypoxia,
especially during the early stages of shock. Consistent
with that study, 71 % of the patients in our study had
hyperlactatemia at T0 and half of them had an elevated
Cv-aCO2/Da-vO2. Interestingly, hyperlactatemic patients
evolving with a high Cv-aCO2/Da-vO2 at T6 (i.e., after
initial resuscitation) had a lower VO2 compared with
those evolving with normal Cv-aCO2/Da-vO2, despite
Table 2 Clinical outcomes
Variable Group 1 (n = 42) Group 2 (n = 42) Group 3 (n = 23) Group 4 (n = 28) p
SOFA day 1 14.5 (10.0–16.3)**} 13.0 (9.0–15.0) 9.0 (8.0 –11.0)** 7.5 (5.8–10.0)} \0.001
SOFA day 3 11.0 (8.0–13.0)**} 8.0 (5.0–11.3) 5.0 (3.0–9.0)** 3.5 (2.0–6.0)} \0.001
ICU length of stay, days 7.0 (1.0–12.0) 4.5 (2.0–10.0) 6.0 (4.0–8.0) 7.5 (3.0–12.5) 0.44
Ventilator-free days 0 (0–12)*}** 20 (0–25) 24 (14–26) 25 (20–28) \0.001
Mortality observed/expected at
day 28, n (% inside group)
30 (71.4)/18 (42.9)*}** 17 (40.5)/18 (42.9) 9 (39.1)/10 (43.5)n 2 (7.1)/12 (42.8)}n \0.001
Data are presented as median (25–75th percentiles) except for mortality.
ICU length of stay is reported for both alive and dead patients
SOFA Sequential Organ Failure Assessment, ICU intensive care unit
* p\ 0.05 for groups 1 vs. 2
** p\ 0.05 for groups 1 vs. 3
} p\ 0.05 for groups 1 vs. 4
 p\ 0.05 for groups 2 vs. 3
 p\ 0.05 for groups 2 vs. 4
n p\ 0.05 for groups 3 vs. 4
Fig. 1 Sequential Organ Failure Assessment (SOFA) scores at
day 3 for predefined groups. Data presented as median (per-
centiles). Patients were separated into four groups according to
lactate and Cv-aCO2/Da-vO2 ratio measured after the first 6 h of
resuscitation: group 1, lactate C2.0 mmol/L and Cv-aCO2/Da-vO2
ratio [1.0; group 2, lactate C2.0 mmol/L and Cv-aCO2/Da-vO2
ratio B1.0; group 3, lactate \2.0 mmol/L and Cv-aCO2/Da-vO2
ratio[1.0; and group 4, lactate\2.0 mmol/L and Cv-aCO2/Da-vO2
ratio B1.0. Kruskal–Wallis one-way ANOVA, p\ 0.001.
**p\ 0.01 by Tukey–Kramer showing differences between
groups 1 vs. 3 and 1 vs. 4
Fig. 2 Survival probabilities up to day 28 according to lactate and
Cv-aCO2/Da-vO2 after 6 h of resuscitation. Log rank (Mantel–
Cox) = 31.39, p\ 0.0001. Group 1, lactate C2.0 mmol/L and Cv-
aCO2/Da-vO2 ratio [1.0; group 2, lactate C2.0 mmol/L and Cv-
aCO2/Da-vO2 ratio B1.0; group 3, lactate \2.0 mmol/L and Cv-
aCO2/Da-vO2 ratio [1.0; and group 4, lactate \2.0 mmol/L and
Cv-aCO2/Da-vO2 ratio B1.0
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similar DO2 values. This suggests that a high Cv-aCO2/
Da-vO2 coupled with hyperlactatemia could identify on-
going VO2/DO2 dependence. In agreement with this
concept, Monnet et al. [38] recently reported that VO2
increased after fluid administration only in patients with a
pre-fluid high Pv-aCO2/DavO2 ratio. In other words, a
VCO2/VO2 ratio estimated by the Pv-aCO2/DavO2 or the
Cv-aCO2/DavO2 could be used to predict fluid respon-
siveness at the tissue level.
Intriguingly, both Cv-aCO2/Da-vO2 and lactate levels
were independent factors determining clinical outcomes, at
T0 and T6. As expected, patients with combined increase in
Cv-aCO2/Da-vO2 and lactate had the worse outcome, while
patients with both variables normal had the best outcomes.
Interestingly, patients attaining normal lactate levels at T6
but with a high Cv-aCO2/Da-vO2 had a similar incidence of
multiorgan dysfunction and unfavorable clinical outcomes
as hyperlactatemic patients with a Cv-aCO2/Da-vO2 B1.0.
This further emphasizes the additive value of both indices.
Recent human studies suggest that Pv-aCO2 may iden-
tify persistent perfusion derangements in apparently
resuscitated septic shock patients [18, 20, 39]. The sim-
plicity of Pv-aCO2 measurement makes it an attractive tool
to guide resuscitation in the clinical setting. However, the
Pv-aCO2 is a physiologically complex measurement, as the
relationship between the CO2 partial pressure (PCO2) and
the CO2 content (CCO2) is affected by O2 saturation, i.e.,
the Haldane effect [21]. Accordingly, clinical interpretation
of the Pv-aCO2 can be difficult since its increase can be
observed in both aerobic and anaerobic conditions.
Another important question is whether Pv-aCO2/Da-
vO2 can be used as a surrogate of Cv-aCO2/Da-vO2. This
approach, used by several investigators [22, 38], assumes
that CO2 partial pressure (PCO2) keeps a quasi-linear re-
lationship with CO2 content (CCO2) over the physiological
range of PCO2, i.e., along the steep portion of the CO2
dissociation curve. However, the relationship between
PCO2 and CCO2 becomes non-linear if oxygen saturation,
arterial-venous pH difference, and/or hemoglobin con-
centrations change. In this respect, several studies [21, 40]
reported dissociation between CCO2 and PCO2 in the
splanchnic region when CCO2 decreased in the venous
splanchnic effluent while PCO2 paradoxically increased
during increases of splanchnic blood flow. In fact, they
showed that venous to arterial PCO2 differences could in-
crease or decrease for identical blood flow increases. Thus,
depending on the basal venous oxygen saturation, the
Table 3 Multivariate logistic regression for predictors of mortality at day 28
T0 T6 T6 (for SvO2 C65 %)
a
RR 95 % CI p RR 95 % CI p RR 95 % CI p
Cv-aCO2/Da-vO2 3.85 1.60–9.27 0.003 3.97 1.54–10.24 0.004 5.71 1.20–27.19 0.03
Lactate, mmol/L 1.19 0.98–1.44 0.09 1.58 1.13–2.22 0.008 2.41 1.22–4.76 0.01
VO2, mL/min/m
2 1.00 0.98–1.01 0.59 0.99 0.98–1.00 0.24 1.01 0.99–1.02 0.30
DO2, mL/min/m
2 1.00 0.99–1.00 0.69 1.00 0.99–1.01 0.43 1.00 0.99–1.01 0.67
SvO2, % 0.97 0.90–1.04 0.35 0.93 0.86–1.01 0.06
CI, L/min/m2 0.82 0.44–1.53 0.54 0.94 0.39–2.26 0.89 1.28 0.33–4.96 0.72
APACHE II 1.08 0.98–1.19 0.09 1.03 0.94–1.14 0.54 0.94 0.80–1.10 0.45
Age, years 1.03 0.99–1.06 0.14 1.02 0.98–1.06 0.38 1.10 0.99–1.21 0.06
Time before T0, h 0.62 0.36–1.04 0.07 0.72 0.41–1.27 0.26 0.63 0.29–1.40 0.25
Gender 0.45 0.16–1.27 0.13 0.77 0.24–2.45 0.66 0.15 0.03–0.99 0.05
Fluids, mL 1.00 0.99–1.01 0.84 1.00 1.00–1.01 0.93 1.00 0.99–1.00 0.81
Norepinephrine, lg/kg/min 1.78 0.23–13.94 0.58 0.41 0.06–2.89 0.37 0.25 0.01–7.56 0.42
MAP, mmHg 0.96 0.92–1.01 0.09 0.98 0.92–1.05 0.58 0.98 0.89–1.09 0.71
Cv-CO2/Da-vO2 mixed venous-to-arterial carbon dioxide to arte-
rial-venous oxygen content differences ratio, DO2 oxygen delivery,
VO2 oxygen consumption, SvO2 mixed-venous oxygen saturation,
CI cardiac index, APACHE II Acute Physiology and Chronic
Health Evaluation II, MAP mean arterial pressure
a Analysis just for patients attaining SvO2[65 % at T6
Fig. 3 Receiver operating characteristics (ROC) curves for pre-
diction of mortality at day 28 for models including or not Cv-aCO2/
Da-vO2 ratio. The ‘‘large model’’ included Cv-aCO2/Da-
vO2 ? lactate levels. The ‘‘short model’’ included lactate levels
but not Cv-aCO2/Da-vO2. Both models also included oxygen
consumption (VO2), oxygen delivery (DO2), mixed-venous oxygen
saturation (SvO2), cardiac index, APACHE II, age, time before T0,
gender, fluids administered, norepinephrine dose, and mean arterial
pressure. Likelihood ratio test, v2 = 17.81, p\ 0.001. Differences
between AUCs, C statistic, v2 4.52, p = 0.03
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Haldane effect may cause a decrease or increase in the
respective venous to arterial PCO2 difference in response to
the same changes in blood flow and metabolism [40]. Thus,
theoretically Cv-aCO2/Da-vO2 is not equivalent to Pv-
aCO2/Da-vO2 especially during low PCO2 and SvO2 con-
ditions. Importantly, despite the similarities in the time-
course of the Pv-aCO2/Da-vO2 and the Cv-aCO2/Da-vO2
(ESM Figs. 3 and 4), we did not find significant association
with day-28 mortality for the Pv-aCO2/Da-vO2 when it was
included instead of Cv-aCO2/Da-vO2 in the logistic re-
gression (ESM Table 2). An additional analysis
simultaneously including the Pv-aCO2/Da-vO2 and the Cv-
aCO2/Da-vO2 demonstrated that despite the former being
significantly associated with mortality in the univariate
analysis, it was not maintained in the multivariate analysis
(ESM Table 3). Nevertheless, despite having ruled out
mathematical collinearity between Pv-aCO2/Da-vO2 and
Cv-aCO2/Da-vO2 in the model, it would be debatable to
refuse that any collinearity might exist between two vari-
ables tightly related. However, we admit that Pv-aCO2/Da-
vO2 could be equivalent to Cv-aCO2/Da-vO2 when PCO2,
pH, and SvO2 approximate to normality, which occurs
frequently. Cv-aCO2/DavO2 is an approximation of respi-
ratory quotient, and thus it has a strong physiological
meaning. Even though it is more complicated to compute, it
is easier to interpret, with values above 1 suggesting
anaerobic metabolism. Admittedly, computations of CO2
content and DavO2 are cumbersome and subject to an im-
portant risk of errors due to the number of variables
included in the formulas. Nevertheless, our data suggest
that the influence of measurement errors is limited as it
correctly identified patients at increased risk of death.
Nowadays critically ill patients admitted to the ICU often
exhibit normal or near-normal venous oxygen saturations
[11]. Interestingly, when we studied only the patients at-
taining SvO2[65 %, Cv-aCO2/Da-vO2 and lactate levels
were still independent predictors of outcomes. Thus, Cv-
aCO2/Da-vO2 could be a useful resuscitation variable in both
low and normal SvO2 conditions.
We acknowledge some limitations of our study. First,
both Cv-aCO2 and Da-vO2 are global variables and they
may not represent regional or local perfusion derange-
ments. Thus, tissue hypoperfusion inducing local CO2
accumulation may occur even when systemic venous CO2
remains normal. Second, the Cv-aCO2 may not increase
during conditions of tissue hypoxia associated with high
blood flow, even if CO2 production is increased due to
anaerobic metabolism, as venous blood flow may be suf-
ficient to wash out the CO2 generated by hypoxic cells [41].
In these patients, the combination with lactate levels is
useful to overcome this shortcoming. Finally, our obser-
vations were restricted to a relatively small sample of septic
shock patients and although our results sound biologically
plausible, they should be confirmed in future physiological
studies to better understand the significance of the Cv-
aCO2/Da-vO2 ratio during early stages of septic shock.
Conclusion
Combination of Cv-aCO2/Da-vO2 and lactate measure-
ments at early stages of resuscitation can identify risk of
adverse outcomes in septic shock. The Cv-aCO2/Da-vO2
ratio may become a potential resuscitation goal in patients
with septic shock.
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